(Press-News.org) Dec. 8, 2023
Contact:
Bill Lubinger
216.368.4443
william.lubinger@case.edu
Ansley Kelm
678-313-6525
Ansley.Kelm@UHhospitals.org
CLEVELAND—Researchers at Case Western Reserve University and University Hospitals have identified an enzyme that blocks insulin produced in the body—a discovery that could provide a new target to treat diabetes.
Their study, published Dec. 5 in the journal Cell, focuses on nitric oxide, a compound that dilates blood vessels, improves memory, fights infection and stimulates the release of hormones, among other functions. How nitric oxide performs these activities had long been a mystery.
The researchers discovered a novel “carrier” enzyme (called SNO-CoA-assisted nitrosylase, or SCAN) that attaches nitric oxide to proteins, including the receptor for insulin action.
They found that the SCAN enzyme was essential for normal insulin action, but also discovered heightened SCAN activity in diabetic patients and mice with diabetes. Mouse models without the SCAN enzyme appeared to be shielded from diabetes, suggesting that too much nitric oxide on proteins may be a cause of such diseases.
“We show that blocking this enzyme protects from diabetes, but the implications extend to many diseases likely caused by novel enzymes that add nitric oxide,” said the study’s lead researcher Jonathan Stamler, the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Professor of Cardiovascular Innovation at the Case Western Reserve School of Medicine and president of Harrington Discovery Institute at University Hospitals. “Blocking this enzyme may offer a new treatment.”
Given the discovery, next steps could be to develop medications against the enzyme, he said.
The research team included Hualin Zhou and Richard Premont, both from Case Western Reserve School of Medicine and University Hospitals, and students Zack Grimmett and Nicholas Venetos from the university’s Medical Science Training Program.
Many human diseases, including Alzheimer’s, cancer, heart failure and diabetes, are thought to be caused or accelerated by nitric oxide binding excessively to key proteins. With this discovery, Stamler said, enzymes that attach the nitric oxide become a focus.
With diabetes, the body often stops responding normally to insulin. The resulting increased blood sugar stays in the bloodstream and, over time, can cause serious health problems. Individuals with diabetes, the Centers for Disease Control reports, are more likely to suffer such conditions as heart disease, vision loss and kidney disease.
But the reason that insulin stops working isn’t well understood.
Excessive nitric oxide has been implicated in many diseases, but the ability to treat has been limited because the molecule is reactive and can’t be targeted specifically, Stamler said.
“This paper shows that dedicated enzymes mediate the many effects of nitric oxide,” he said. “Here, we discover an enzyme that puts nitric oxide on the insulin receptor to control insulin. Too much enzyme activity causes diabetes. But a case is made for many enzymes putting nitric oxide on many proteins, and, thus, new treatments for many diseases.”
###
Case Western Reserve University is one of the country's leading private research institutions. Located in Cleveland, we offer a unique combination of forward-thinking educational opportunities in an inspiring cultural setting. Our leading-edge faculty engage in teaching and research in a collaborative, hands-on environment. Our nationally recognized programs include arts and sciences, dental medicine, engineering, law, management, medicine, nursing and social work. About 6,200 undergraduate and 6,100 graduate students comprise our student body. Visit case.edu to see how Case Western Reserve thinks beyond the possible.
About University Hospitals / Cleveland, Ohio
Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 21 hospitals (including five joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices in 16 counties throughout northern Ohio. The system’s flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University, the Technion Israel Institute of Technology and National Taiwan University College of Medicine. The main campus also includes the UH Rainbow Babies & Children's Hospital, ranked among the top children’s hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, with more than 3,000 active clinical trials and research studies underway. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including “America’s Best Hospitals” from U.S. News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH is one of the largest employers in Northeast Ohio with more than 30,000 employees. Follow UH on LinkedIn, Facebook and Twitter. For more information, visit UHhospitals.org.
END
New cause of diabetes discovered, offering potential target for new classes of drugs to treat the disease
2023-12-08
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
MD Anderson and Rigel Pharmaceuticals announce strategic alliance to advance olutasidenib in AML and other cancers
2023-12-08
HOUSTON and SOUTH SAN FRANCISCO, Calif. ― The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers.
The alliance brings together MD Anderson’s clinical research expertise with Rigel’s differentiated targeted molecule. Under the strategic collaboration, Rigel and MD Anderson will evaluate the potential of olutasidenib to treat newly diagnosed and relapsed ...
New insights into Zebra mussel attachment fibers offer potential solutions to combat invasive species, develop sustainable materials
2023-12-08
A recent study from researchers in Canada and Germany has revealed that an unlikely event, occurring over 12 million years ago played an important role in shaping one of Canada’s most damaging invasive species.
Zebra and quagga mussels, belonging to the Dreissenid family, are widespread freshwater invasive species throughout North America that present a significant danger to native ecosystems by competing for resources. Using a fibrous anchor called a byssus, Dreissenid mussels contribute to biofouling on surfaces and obstruct intake structures in power stations and water treatment plants.
“This new study, which looks into the way these mussels stick to surfaces, may help improve ...
A micro-ring resonator with big potential
2023-12-08
EPFL researchers have developed a hybrid device that significantly improves existing, ubiquitous laser technology.
The team at EPFL’s Photonic Systems Laboratory (PHOSL) has developed a chip-scale laser source that enhances the performance of semiconductor lasers while enabling the generation of shorter wavelengths. This pioneering work, led by Professor Camille Brès and postdoctoral researcher Marco Clementi from EPFL’s School of Engineering represents a significant advance in the field of photonics, with implications for telecommunications, metrology, and other high-precision applications.
The ...
Skipping adjuvant radiotherapy may not impact risk of recurrence or progression in patients with low-risk DCIS
2023-12-08
SAN ANTONIO – Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.
“Nearly all women with DCIS—a noninvasive form of breast cancer—will have their cancer successfully removed, but some women will have a high risk of the disease returning or progressing to invasive breast cancer,” said Seema A. Khan, MD, a professor of surgery and the Bluhm Family ...
Some breast cancer survivors may safely de-escalate mammography three years after surgery
2023-12-08
Women 50 or older who de-escalated to less-frequent mammography three years after curative surgery for early-stage breast cancer had similar outcomes to women who received annual mammography, according to results from the Mammo-50 trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.
Both U.S. and U.K. guidelines recommend annual breast cancer screening following surgery to remove early-stage breast cancer; in the U.S., annual mammography is recommended indefinitely, and in the U.K., it is recommended for five years, followed by screening every three years for patients 50 years and older.
However, the optimal screening schedule has yet to ...
Potentially targetable fusion RNAs may be more common in metastatic breast cancer than previously realized
2023-12-08
SAN ANTONIO – Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable, according to results presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.
Fusion mutations occur when a portion of one gene becomes fused to a portion of another, which can create gene products with new functions. They are common in cancer types that are characterized by genomic rearrangements and structural damage to the DNA, including breast cancer.
“Fusion RNAs may serve as ...
Study reveals insights into tacking diabetic kidney disease - with a side order of how anti-obesity drugs work
2023-12-08
Data from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found to be so effective. Importantly, the data also reveals how anti-obesity drugs like Ozempic, actually work, which to date have been a mystery.
In early November the FLOW trial of the drug semaglutide on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease was halted ahead of schedule because of the drug’s efficacy.
Part of the rationale for the cessation of the trial could be explained by ...
Study on battery recycling shows China is in 1st place
2023-12-08
With the increase in the production of batteries for electric vehicles, demand is also rising for the necessary raw materials. In view of risks to the supply chain, environmental problems and precarious working conditions which are all associated with the mining and transportation of these materials, the recycling of battery materials has become an important issue in research, politics and industry. Prof. Stephan von Delft from the University of Münster (Germany) heads a team of researchers from the fields of science ...
Veins of bacteria could form a self-healing system for concrete infrastructure
2023-12-08
In hopes of producing concrete structures that can repair their cracks, researchers from Drexel University’s College of Engineering are putting a new twist on an old trick for improving the durability of concrete. Fiber reinforcement has been around since the first masons were mixing horsehair into their mud. But the Drexel research team is taking this method to the next level by turning reinforcing fibers into a living tissue system that rushes concrete-healing bacteria to the site of cracks to repair the damage.
Recently reported in the journal Construction ...
First observation of structures resulting from 3D domain swapping in antibody light chains
2023-12-08
Ikoma, Japan – Antibodies (immunoglobulins) are Y-shaped proteins that recognize and neutralize specific pathogens. Their ability to target specific molecules or cells has made them promising candidates for future drug development. However, their light chains—parts of the antibody that contribute to recognizing and binding to specific antigens—misfold and aggregate, leading to amyloidosis, a condition that brings about complications and tissue dysfunction in the body. In the context of drug development, antibody aggregation can compromise their capacity to bind to antigens ...